Filing Details
- Accession Number:
- 0001012975-19-000254
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-01 17:35:14
- Reporting Period:
- 2019-04-01
- Accepted Time:
- 2019-04-01 17:35:14
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1357874 | Precision Biosciences Inc | DTIL | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1278411 | S Corey Goodman | C/O Venbio Partners, Llc 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No | |
| 1329161 | J Robert Adelman | C/O Venbio Partners, Llc 1700 Owens Street, Suite 595 San Francisco CA 94158 | Yes | No | Yes | No | |
| 1504130 | Venbio Global Strategic Fund, L.p. | C/O Venbio Partners, Llc 1700 Owens Street, Suite 595 San Francisco CA 94158 | Yes | No | Yes | No | |
| 1770834 | Venbio Global Strategic Gp, L.p. | C/O Venbio Partners, Llc 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No | |
| 1770835 | Venbio Global Strategic Gp, Ltd. | C/O Venbio Partners, Llc 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-04-01 | 50,000 | $16.00 | 50,000 | No | 4 | P | Indirect | See footnote |
| Common Stock | Acquisiton | 2019-04-01 | 3,747,623 | $0.00 | 3,797,623 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2019-04-01 | 467,518 | $0.00 | 4,265,141 | No | 4 | C | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2019-04-01 | 8,000,000 | $0.00 | 3,747,623 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2019-04-01 | 998,004 | $0.00 | 467,518 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.
- venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.
Billionaire Hedge Funds
